GlassScriptPhysician profile
Theresa Durchhalter
NPI 1427419241
$17,739.84
in general payments reported to CMS, 2019-2025
33 companies · $5,699 in 2025
The $5,699 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.93 · 2021: $1,014 · 2022: $2,127 · 2023: $3,371 · 2024: $5,499 · 2025: $5,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,281.99 |
| Education | $286.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $2,728.27 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,683.34 | 2021-2025 | Winlevi, Absorica Ld |
| Abbvie INC. | $1,275.54 | 2021-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $1,275.01 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $970.18 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $967.79 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $822.29 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $817.29 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $748.17 | 2021-2025 | |
| Merz North America, INC. | $712.49 | 2022-2025 | Xeomin |
| Genzyme Corporation | $622.10 | 2021-2025 | |
| Ucb, INC. | $594.48 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $561.23 | 2022-2024 | Vtama |
| Amgen INC. | $501.30 | 2022-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $446.61 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $403.91 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $377.39 | 2022-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $347.53 | 2022-2023 | |
| Almirall LLC | $309.81 | 2021-2025 | Klisyri |
| Biofrontera INC. | $285.65 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $194.28 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $175.85 | 2021-2025 | Cabtreo, Duobrii |
| Vyne Pharmaceuticals INC. | $149.75 | 2020-2021 | |
| Journey Medical Corporation | $141.90 | 2022-2025 | |
| Revance Therapeutics, INC. | $126.06 | 2024-2025 | Daxxify |
| Epi Health, LLC | $116.20 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Verrica Pharmaceuticals INC. | $83.90 | 2023-2024 | Ycanth |
| Organon LLC | $66.38 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $39.53 | 2024-2025 | Xtrac |
| Cipher Pharmaceuticals US LLC | $39.07 | 2025 | Natroba, Spinosad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.14 | 2023-2024 | Spevigo |
| Sanofi US Services INC. | $21.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresa Durchhalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.